Fuchs endothelial corneal dystrophy (FECD) is the leading indication for corneal transplantation worldwide. It is characterized by the accumulation of guttae and progressive loss of corneal endothelial cells, leading to corneal edema and visual impairment. Endothelial keratoplasty remains the standard treatment; however, graft shortages have driven the development of cell-based therapies involving the injection of cultured endothelial cells. A key unresolved issue is whether removal of the pathological endothelium prior to injection improves cell adhesion. Clinical data are limited and sometimes contradictory, particularly regarding endothelial polishing. The actual effectiveness of this procedure in removing guttae and enhancing the survival of injected cells remains uncertain. Therefore, an in vivo clinical evaluation is required to assess its impact on guttae removal.

Inclusion Criteria:

• Patient affiliated with or entitled to a social security scheme
• Patient scheduled for endothelial keratoplasty for Fuchs endothelial corneal dystrophy
• Patient having received full information and having provided written informed consent

Exclusion Criteria:

• Pregnant women
• Adults under legal protection (guardianship/curatorship) or unable to provide informed consent